FULC Fulcrum Therapeutics, Inc.
Healthcare$6.76+2.89%ClosedMarket Cap: $365.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.50
P/S
0.00
EV/EBITDA
-3.99
DCF Value
$3.01
FCF Yield
-18.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.8%
ROA
-21.9%
ROIC
-25.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-22.2M | $-18.9M | $— | — |
| Q4 null | $0.00 | Infinity% | $-22.7M | $-20.3M | $— | — |
| FY null | $0.00 | -Infinity% | $-84.8M | $-74.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-21.9M | $-19.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-19.8M | $-17.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-20.4M | $-17.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-19.4M | $-16.6M | $— | — |
| FY null | $80.0M | 20.8% | $-21.9M | $-9.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-25.1M | $-21.7M | $— | — |
| Q2 null | $80.0M | 78.4% | $52.5M | $55.4M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-29.8M | $-26.9M | $— | — |
| Q4 2023 | $871.0K | 41.7% | $-28.0M | $-24.8M | $-0.40 | — |